Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
CHRS

CHRS - Coherus Biosciences Inc Stock Price, Fair Value and News

1.63USD-0.04 (-2.40%)Market Closed

Market Summary

CHRS
USD1.63-0.04
Market Closed
-2.40%

CHRS Alerts

  • Temasek Holdings (Private) Ltd reported owning 5.4% of CHRS [2024-05-22]

CHRS Stock Price

View Fullscreen

CHRS RSI Chart

CHRS Valuation

Market Cap

185.9M

Price/Earnings (Trailing)

-3.13

Price/Sales (Trailing)

0.62

EV/EBITDA

5.53

Price/Free Cashflow

-1.21

CHRS Price/Sales (Trailing)

CHRS Profitability

EBT Margin

-19.77%

Return on Equity

72.44%

Return on Assets

-7.76%

Free Cashflow Yield

-82.43%

CHRS Fundamentals

CHRS Revenue

Revenue (TTM)

301.9M

Rev. Growth (Yr)

137.58%

Rev. Growth (Qtr)

-15.8%

CHRS Earnings

Earnings (TTM)

-59.3M

Earnings Growth (Yr)

235.85%

Earnings Growth (Qtr)

229.15%

Breaking Down CHRS Revenue

Last 7 days

-1.2%

Last 30 days

-15.2%

Last 90 days

-29.6%

Trailing 12 Months

-59.4%

How does CHRS drawdown profile look like?

CHRS Financial Health

Current Ratio

1.17

CHRS Investor Care

Shares Dilution (1Y)

42.42%

Diluted EPS (TTM)

-0.78

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024301.9M000
2023183.4M181.9M211.1M257.2M
2022303.6M276.1M239.1M211.0M
2021442.7M394.6M363.6M326.6M
2020435.1M487.4M489.3M475.8M
2019284.9M308.6M332.3M356.1M
20170213.8M237.5M261.2M
201636.6M43.8M199.5M190.1M
201533.3M35.2M26.3M30.0M
20145.8M10.3M25.8M31.1M
20132.1M2.3M2.5M2.8M
20120001.9M

Tracking the Latest Insider Buys and Sells of Coherus Biosciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 09, 2024
wahlstrom mats
gifted
-
-
-99,988
-
Feb 09, 2024
wahlstrom mats
gifted
-
-
99,988
-
Feb 01, 2024
wahlstrom mats
acquired
100,000
1.667
59,988
-
Jan 20, 2024
lanfear dennis m
sold (taxes)
-27,371
2.44
-11,218
president & ceo
Jan 20, 2024
mcmichael bryan j
sold (taxes)
-4,165
2.44
-1,707
see remarks
Jan 20, 2024
reider paul
sold (taxes)
-11,843
2.44
-4,854
chief commercial officer
Jan 07, 2024
mcmichael bryan j
sold (taxes)
-4,899
2.87
-1,707
see remarks
Jan 04, 2024
reider paul
sold (taxes)
-6,643
2.92
-2,275
chief commercial officer
Jan 04, 2024
lanfear dennis m
sold (taxes)
-34,400
2.92
-11,781
president & ceo
Dec 31, 2023
stilwell mcdavid
sold (taxes)
-61,405
3.33
-18,440
chief financial officer

1–10 of 50

Which funds bought or sold CHRS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.35
8,208
51,208
0.01%
May 20, 2024
Virtu Financial LLC
new
-
94,000
94,000
0.01%
May 17, 2024
Ikarian Capital, LLC
sold off
-100
-1,134,820
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-89.95
-324,494
25,226
-%
May 16, 2024
JANE STREET GROUP, LLC
unchanged
-
231,120
1,916,210
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-34.72
-980,340
864,133
-%
May 15, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
sold off
-100
-13,320
-
-%
May 15, 2024
Royal Bank of Canada
reduced
-85.47
-96,000
11,000
-%
May 15, 2024
BOOTHBAY FUND MANAGEMENT, LLC
reduced
-78.98
-285,989
50,821
-%
May 15, 2024
Bayesian Capital Management, LP
new
-
56,306
56,306
-%

1–10 of 40

Are Funds Buying or Selling CHRS?

Are funds buying CHRS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CHRS
No. of Funds

Unveiling Coherus Biosciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 22, 2024
temasek holdings (private) ltd
5.4%
6,220,552
SC 13G/A
Feb 14, 2024
citadel advisors llc
1.6%
6
SC 13G/A
Feb 14, 2024
alliancebernstein l.p.
0.1%
156,000
SC 13G/A
Feb 13, 2024
vanguard group inc
9.30%
10,357,412
SC 13G/A
Jan 24, 2024
blackrock inc.
10.8%
12,074,695
SC 13G/A
Jan 22, 2024
state street corp
1.85%
2,064,326
SC 13G/A
Dec 07, 2023
jpmorgan chase & co
0.1%
124,796
SC 13G/A
Oct 06, 2023
blackrock inc.
10.9%
11,645,835
SC 13G/A
May 19, 2023
citadel advisors llc
6.1%
6
SC 13G
Feb 14, 2023
perceptive advisors llc
0%
0
SC 13G/A

Recent SEC filings of Coherus Biosciences Inc

View All Filings
Date Filed Form Type Document
Jun 05, 2024
8-K
Current Report
Jun 05, 2024
3
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading
Jun 05, 2024
4
Insider Trading

Peers (Alternatives to Coherus Biosciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
52.5B
6.8B
-17.75% 15.65%
-8.8
7.67
-64.45% -224.75%
28.2B
2.0B
50.83% 15.66%
-84.91
14.07
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.2B
2.5B
12.78% -8.91%
78.69
6.54
13.74% 186.89%
14.3B
3.8B
11.22% 2.07%
19.2
3.8
8.58% 129.81%
MID-CAP
4.7B
524.1M
-5.39% -54.95%
-11.17
8.9
394.93% 39.61%
4.3B
107.9M
-17.68% 46.87%
-7.87
48.09
54.84% -28.31%
3.7B
251.0M
4.40% -10.91%
-12.58
14.85
73.58% -86.73%
3.4B
240.7M
9.49% -22.70%
-7.15
12.77
-1.03% -213.92%
2.6B
813.8M
4.41% -35.25%
-1.5K
3.22
56.43% 98.83%
2.0B
996.6M
-9.61% 109.10%
-4.93
1.97
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.09% 16.96%
27.9
4.42
60.38% -34.49%
464.6M
881.7K
-3.44% 394.54%
-13.76
481.06
-77.61% 33.36%
206.5M
4.2M
-27.55% 54.46%
-1.65
49.65
-66.30% 48.24%
18.0M
2.1M
-4.57% 211.94%
-0.78
7.61
-13.45% 69.54%

Coherus Biosciences Inc News

Latest updates
MarketBeat5 hours ago
Yahoo Movies UK22 Jun 202411:00 pm
The Motley Fool4 months ago

Coherus Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-15.8%77,063,00091,524,00074,568,00058,716,00032,436,00045,352,00045,424,00060,151,00060,115,00073,371,00082,503,00087,643,00083,034,000110,419,000113,551,000135,674,000116,180,000123,871,500111,684,00083,400,00037,100,000
Costs and Expenses-25.5%119,588,000160,429,000106,574,00093,259,000100,181,00096,845,000125,873,000104,164,000141,040,000112,918,000115,290,000111,807,000250,394,00093,994,00079,835,00070,364,00075,312,000----
Operating Expenses---------------79,835,00070,364,00075,312,00078,823,00059,843,00055,940,00053,697,000
  S&GA Expenses14.2%56,532,00049,494,00048,224,00045,144,00049,153,00053,621,00044,831,00051,276,00048,753,00050,052,00039,925,00040,345,00039,391,00037,693,00031,984,00034,052,00035,350,00036,070,00031,828,00036,456,00032,683,000
  R&D Expenses8.0%28,470,00026,368,00025,647,00023,267,00034,154,00029,022,00045,808,00041,611,00082,917,00050,762,00054,085,00054,766,000203,492,00044,628,00038,851,00026,173,00033,107,00034,948,00021,568,00018,883,00018,789,000
EBITDA Margin94.1%-0.04-0.75-0.83-1.23-1.28-1.21-1.03-0.72-0.59-0.80-0.56-0.35---------
Interest Expenses4.7%11,116,00010,619,00010,268,0009,943,0009,712,0009,385,0007,540,0006,580,0008,969,0005,793,0005,771,0005,747,0005,648,0005,671,0005,656,0005,408,0004,431,0004,483,0004,469,0004,433,0004,216,000
Income Taxes----380,000----------1,057,500200,0001,300,000900,0002,067,500800,00051,000-
Earnings Before Taxes229.2%102,875,000-79,653,000-40,021,000-42,869,000-75,729,000-58,870,000-86,650,000-50,150,000-96,084,000-45,725,000-38,528,000-29,900,000-172,947,00010,760,50028,116,00060,325,00036,505,00041,271,00047,890,00023,618,000-20,004,000
EBT Margin78.7%-0.20-0.93-1.03-1.45-1.48-1.38-1.17-0.83-0.69-0.88-0.63-0.42---------
Net Income229.2%102,875,000-79,653,000-39,641,000-42,869,000-75,729,000-58,870,000-86,650,000-50,150,000-96,084,000-45,725,000-38,528,000-29,900,000-172,947,0009,708,00027,933,00059,031,00035,572,00039,227,00047,043,00023,567,000-20,004,000
Net Income Margin78.8%-0.20-0.92-1.03-1.45-1.48-1.38-1.17-0.83-0.69-0.88-0.64-0.42---------
Free Cashflow-260.8%-46,800,000-12,971,000-54,300,000-39,015,000-68,884,000-100,040,000-37,546,000-50,917,000-54,660,000-52,790,00013,450,000-603,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets21.3%764630584470402481551546593679742740693842804757467409327240186
  Current Assets31.9%627476444385316381448447512602673660617767727676395343276206159
    Cash Equivalents152.5%26010380.0073.0016.0064.0028727532641736133025954129222519317816510682.00
  Inventory-1.0%62.0063.0067.0064.0049.0039.0028.0032.0037.0038.0038.0040.0052.0044.0035.0027.0016.0010.008.004.002.00
  Net PPE-18.2%4.005.006.007.008.009.0010.0010.008.008.00---10.00-10.007.006.006.006.006.00
  Goodwill-100.0%-1.00-------1.001.001.001.001.001.001.001.001.001.001.001.00
Liabilities2.7%845823717644599618648569581582611583566561548543309304271244225
  Current Liabilities62.3%53833224016912313917114115416532028725814613313011911583.0061.0041.00
Shareholder's Equity57.7%-81.84-193---196-137--13.0098.0013115612828125621315710556.00978-
  Retained Earnings6.5%-1,476-1,579-1,499-1,460-1,417-1,341-1,282-1,196-1,145-1,049-1,004-965-935-762-772-800-859-895-934-981-1,004
  Additional Paid-In Capital0.6%1,3951,3861,3671,2861,2211,2041,1861,1741,1591,1481,1351,1221,0641,0441,0281,0141,0171,001991978967
Shares Outstanding1.1%11311210994.0079.0079.0078.0077.0077.0075.0075.0076.00---------
Float----324---444---837---900---1,400-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-261.5%-46,766-12,937-54,300-38,915-68,732-99,953-37,089-50,037-54,045-52,32213,711-1881,36733,12447,35360,19113,47717,71054,95112,677-56,983
  Share Based Compensation-32.2%7,31910,7989,95310,07712,28211,72612,28213,85012,87910,94611,93911,59516,8849,8739,3079,4259,5557,2728,8337,9929,494
Cashflow From Investing476.0%202,76335,20350,54641,36517,526-129,898-457-880-35,615107,49015,99023,585-285,475210,05616,407-239,248-1,616-6,062-2898,818-15,199
Cashflow From Financing142.3%88736611,10554,3253,8046,59348,867721-1,8551,4871,10146,8522,4395,5134,088210,4223,9231,2003,6833,01081,477
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CHRS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Net revenue$ 77,063$ 32,436
Costs and expenses:  
Cost of goods sold34,58616,874
Research and development28,47034,154
Selling, general and administrative56,53249,153
Total costs and expenses119,588100,181
Loss from operations(42,525)(67,745)
Interest expense(11,116)(9,712)
Gain on Sale Transaction, net (Note 6)153,647 
Other income (expense), net2,8691,728
Income (loss) before income taxes102,875(75,729)
Net income (loss)$ 102,875$ (75,729)
Net Income (Loss) Per Share  
Basic (In dollar per share)$ 0.91$ (0.96)
Diluted (In dollar per share)$ 0.83$ (0.96)
Weighted-average number of shares used in computing net income (loss) per share:  
Basic (In shares)112,749,30679,268,853
Diluted (In shares)125,529,97179,268,853

CHRS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 259,775$ 102,891
Investments in marketable securities 14,857
Trade receivables, net251,951260,522
TSA receivables, net (Note 6)32,194 
Inventory61,97862,605
Prepaid manufacturing7,49823,657
Other prepaids and current assets14,08111,099
Total current assets627,477475,631
Property and equipment, net4,1885,119
Inventory, non-current65,64567,495
Intangible assets, net57,10471,673
Other assets, non-current9,1319,686
Total assets763,545629,604
Current liabilities:  
Accounts payable38,28935,219
Accrued rebates, fees and reserves155,775169,645
TSA payables and other accrued liabilities (Note 6)30,770 
Accrued compensation22,76221,521
Accrued and other current liabilities115,707105,386
Term loans, current175,000 
Total current liabilities538,303331,771
Term loans, non-current72,452246,481
Convertible notes227,220226,888
Lease liabilities, non-current4,6805,328
Other liabilities, non-current2,73412,561
Total liabilities845,389823,029
Commitments and contingencies (Note 9)
Stockholders' deficit:  
Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 113,496,854 and 112,215,260 at March 31, 2024 and December 31, 2023, respectively)1111
Additional paid-in capital1,395,0421,386,312
Accumulated other comprehensive loss(272)(248)
Accumulated deficit(1,476,625)(1,579,500)
Total stockholders' deficit(81,844)(193,425)
Total liabilities and stockholders' deficit$ 763,545$ 629,604
CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
 CEO
 WEBSITEcoherus.com
 INDUSTRYBiotechnology
 EMPLOYEES294

Coherus Biosciences Inc Frequently Asked Questions


What is the ticker symbol for Coherus Biosciences Inc? What does CHRS stand for in stocks?

CHRS is the stock ticker symbol of Coherus Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Coherus Biosciences Inc (CHRS)?

As of Mon Jun 24 2024, market cap of Coherus Biosciences Inc is 185.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CHRS stock?

You can check CHRS's fair value in chart for subscribers.

What is the fair value of CHRS stock?

You can check CHRS's fair value in chart for subscribers. The fair value of Coherus Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Coherus Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CHRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Coherus Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CHRS is over valued or under valued. Whether Coherus Biosciences Inc is cheap or expensive depends on the assumptions which impact Coherus Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CHRS.

What is Coherus Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jun 24 2024, CHRS's PE ratio (Price to Earnings) is -3.13 and Price to Sales (PS) ratio is 0.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CHRS PE ratio will change depending on the future growth rate expectations of investors.